410-P: Therapeutic Profile from the Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study

Autor:	Mark Fuller, Alexander Abitbol, Sanjit K. Bhogal, Lisa Chu, Kathryn Jervis
Rok vydání:	2021
Předmět:	medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Retrospective cohort study Subgroup analysis Type 2 diabetes Disease medicine.disease End stage renal disease Internal medicine Diabetes mellitus Cohort Internal Medicine medicine business Kidney disease
Zdroj:	Diabetes. 70
ISSN:	1939-327X 0012-1797
DOI:	10.2337/db21-410-p
Popis:	Background: Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is associated with an elevated risk of end stage renal disease, cardiovascular disease, hospitalizations, and death. As treatment options for patients with T2D and CKD continue to expand, an analysis of the current distribution of therapies and cardiorenal outcomes is warranted. Methods: The CREDO study was a retrospective cohort study of adults with T2D and CKD, who were seen by an endocrinologist in 2019. Data were retrieved from the Canadian LMC Diabetes Registry, one of the largest endocrine practice groups globally. A subgroup analysis of the CREDO study was performed to describe patients using an ACEi/ARB or an emerging renal therapy (MRA, SGLT2i or GLP-1 RA) for ≥ 6 months, or none of the therapies. Results: In this cohort of 11,816 patients with CKD and T2D, ACEi/ARBs were the most frequently used medication, followed by SGLT2i. Expectantly, a greater number of patients using an ACEi/ARB or MRA had hypertension, and more patients using GLP-1 RA suffered from obesity compared to other subgroups. Patients using ≥ 1 of the therapies showed higher mean eGFR and body weight, similar HbA1c and uACR, and a lower mean LDL-C compared to patients not using any therapy (Table 1). Conclusion: These descriptive findings improve our understanding of the current landscape and treatment patterns amongst patients with CKD and T2D in Canada. Disclosure L. Chu: None. M. Fuller: Employee; Self; Bayer Inc. K. Jervis: Employee; Self; Bayer Inc. S. K. Bhogal: None. A. Abitbol: Advisory Panel; Self; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk Canada Inc., Sanofi, Research Support; Self; Bayer Inc., Speaker’s Bureau; Self; Amgen Canada, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc. Funding Bayer Inc. (21190)
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cdd7b4bce69117100e16d62568424bf4 https://doi.org/10.2337/db21-410-p Zobrazit plný text záznamu